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Cerebellar metastasis of papillary thyroid carcinoma 
detected with somatostatin receptor scintigraphy
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Abstract
Introduction: Distant metastases of papillary thyroid carcinoma (PTC) may lack the ability to concentrate radioiodine. In such cases, 
positive somatostatin receptor scintigraphy might be useful in demonstrating the expression of somatostatin receptors that are potential 
therapeutic targets. To date, only a few cerebellar metastases from PTC have been reported in the literature.
Patient findings: We present an 82-year-old female, in whom an asymptomatic cerebellar metastasis from PTC was diagnosed by means 
of Tc-99m-EDDA/HYNIC-TOC scintigraphy four years after the initial diagnosis. She was previously treated with total thyroidectomy 
and regional lymph node dissection, followed by three cycles of radioiodine therapy. Despite persistently elevated thyroglobulin, no 
specific radioiodine accumulation was found in the whole body post-treatment scan. Tc-99m-EDDA/HYNIC-TOC scintiscan revealed 
foci of increased tracer uptake in the lungs, cervical lymph nodes, and a single focus in the head. Thus, therapy with octreotide LAR was 
initiated. The patient died four months later due to disseminated PTC.
Summary: In this paper, a patient with asymptomatic previously unknown non-iodine avid cerebellar metastasis of PTC diagnosed by 
means of scintigraphy using somatostatin analogue Tc-99m-EDDA/HYNIC-TOC is reported.
Conclusions: Somatostatin receptor scintigraphy might be useful in the visualisation of non-iodine avid PTC metastases and demonstrat-
ing the expression of somatostatin receptors that are potential therapeutic targets. (Endokrynol Pol 2018; 69 (1): 24–27)
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Streszczenie
Wstęp: Odległe przerzuty raka brodawkowatego tarczycy (papillary thyroid carcinoma, PTC) mogą nie wykazywać zdolności do gromadzenia 
radiojodu. W takich przypadkach użytecznym badaniem może być scyntygrafia receptorów somatostatynowych, która może wykazać 
ekspresję receptorów somatostatyny będących potencjalnym celem terapeutycznym. Dotychczas opisano zaledwie kilka przypadków 
przerzutów PTC do móżdżku.
Opis przypadku: U pacjentki w wieku 82 lat cztery lata po ustaleniu wstępnej diagnozy wykryto bezobjawowy przerzut PTC do móżdżku 
za pomocą badania scyntygraficznego z użyciem znacznika Tc-99m-EDDA/HYNIC-TOC. Wcześniejsze leczenie chorej obejmowało cał-
kowitą tyroidektomię z resekcją regionalnych węzłów chłonnych, po której zastosowano trzy cykle radioterapii. Mimo stale podwyższo-
nego stężenia tyreoglobuliny nie stwierdzono miejscowego gromadzenia radiojodu w scyntygrafii całego ciała wykonanej po leczeniu. 
Przeprowadzone później badanie scyntygraficzne z użyciem Tc-99m-EDDA/HYNIC-TOC wykazało ogniska zwiększonego wychwytu 
znacznika w płucach i węzłach chłonnych szyi, a także pojedyncze ognisko w móżdżku. W związku z wynikiem badania rozpoczęto 
leczenie oktreotydem LAR. Chora zmarła cztery miesiące później z powodu rozsianego PTC.
Podsumowanie: W tej pracy opisano przypadek chorej z bezobjawowym, niewykrytym wcześniej niejodochwytnym przerzutem do 
móżdżku raka brodawkowatego tarczycy, który został rozpoznany za pomocą badania scyntygraficznego z użyciem analogu somatosta-
tyny Tc-99m-EDDA/HYNIC-TOC.
Wnioski: Scyntygrafia receptorów somatostatynowych może być użyteczna do wizualizacji niejodochwytnych przerzutów PTC i wy-
krywania ekspresji receptorów somatostatynowych, które są potencjalnym celem terapeutycznym. (Endokrynol Pol 2018; 69 (1): 24–27)
Słowa kluczowe: zróżnicowany rak tarczycy, rak brodawkowaty tarczycy, przerzuty do móżdżku, receptory somatostatynowych,  
scyntygrafia receptorów somatostatynowych
Introduction
Distant metastases occur rarely in patients with differ-
entiated thyroid carcinoma (DTC). Brain metastases are 
very rare and cerebellar metastases are extremely rare 
[1–3]. Usually brain metastases are detected by means 
of radioiodine whole-body scan (WBS) or magnetic 
resonance.
Somatostatin receptor scintigraphy (SRS) using ra-
diolabelled somatostatin analogues has been employed 
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in the evaluation of some patients with advanced 
DTC with the aim of visualisation of non-iodine avid 
metastases. In the last decade, Tc-99m-labeled soma-
tostatin analogues were developed, which replaced 
In-111-DTPA-octreotide (OctreoScan) in some centres 
[4–6]. Tc-99m-EDDA/HYNIC-TOC demonstrated rela-
tively high sensitivity and specificity in the detection 
of recurrence in patients with elevated thyroglobulin 
and negative WBS [7].
We hereby report a patient in whom an asympto-
matic non-iodine avid cerebellar metastasis from DTC 
was diagnosed by means of scintigraphy using soma-
tostatin analogue Tc-99m-EDDA/HYNIC-TOC.
Patient
A 78-year-old Caucasian female was diagnosed with 
advanced papillary thyroid carcinoma (PTC) and sub-
jected to total thyroidectomy with regional lymph node 
dissection (staging pT4N1M0), followed by L-thyroxine 
suppressive therapy. Subsequently, radioiodine ablation 
with 90 mCi was performed. The post-treatment WBS 
demonstrated slight radioiodine accumulation in the 
cervical lymph nodes, and persistent structural disease 
in the local lymph nodes was treated surgically. Later, 
radioiodine therapy was repeated twice due to persis-
tent elevation of thyroglobulin (Tg), so the cumulative 
dose was 390 mCi. No specific radioiodine accumula-
tion was found in the WBS performed seven days after 
recent radioiodine therapy. Neck sonography showed 
several enlarged hypoechogenic lymph nodes on the 
left side of the neck. Computed tomography of the 
thorax disclosed three metastatic pulmonary nodules 
of size less than 10 mm.
Due to poor response to radioiodine therapy, pos-
sibly caused by dedifferentiation of PTC cells, other 
forms of treatment had to be considered. At that time 
tyrosine kinase inhibitors were not regularly available 
for the therapy of metastatic thyroid cancer, so we 
needed to consider somatostatin analogues as one of 
the potential therapies. In order to evaluate the status 
of somatostatin receptors in PTC cells,  a Tc-99m-EDDA/
HYNIC-TOC scan was performed. 
In consistence with our protocol, the whole-body 
images were obtained three and 24 h after the IV 
injection of 20 mCi of Tc-99m-EDDA/HYNIC-TOC 
manufactured by Polatom, Poland. The scans were 
registered using an Infinia Hawkeye 4 (General Electric) 
gamma camera. The images showed foci of increased 
tracer uptake in the metastatic cervical lymph nodes 
and lungs, and a small focus of uptake in the head. 
Additional SPECT/CT of the head was performed. It 
showed a focus of increased tracer accumulation in 
the left cerebellar hemisphere 8 mm in size. (Fig. 1). 
Neurological examination did not reveal any signs of 
cerebellar dysfunction. As expression of somatostatin 
receptors was demonstrated in the metastatic foci and 
no radioiodine uptake was observed, experimental 
treatment with somatostatin analogue (Sandostatin 
LAR) was initiated. The therapy was well-tolerated. 
However, the patient died four months later at the age 
of 83 years due to advanced thyroid carcinoma.
Discussion
Metastases to the central nervous system among 
patients with DTC are extremely rare. Among 1200 
patients with thyroid carcinoma treated in our institu-
tion, fewer than 1% had distant metastases detected 
at the time of initial diagnosis. The number of patients 
with distant metastases increases during follow-up 
and accounts for 5-10% of the patients. The most com-
mon locations are lungs (53%) and bones (28%) [8]. 
Brain metastases were present in only 1.5% patients 
treated in M.D. Anderson Cancer Centre over 51 years 
[9]. Most commonly they were located in the cerebral 
hemispheres. The median survival was 4.7 months fol-
lowing the diagnosis of brain metastases [9]. Misaki et 
al. reported nine patients with DTC that metastasised 
to the brain [10]. Lack of radioiodine accumulation in 
Figure 1. Focus of increased accumulation of Tc-99m-EDDA/
HYNIC-TOC in the left cerebellar hemisphere visualised in 
SPECT/CT representing a cerebellar metastasis of papillary 
thyroid carcinoma
Rycina 1. W obrazie badania SPECT/CT zwraca uwagę zwiększone 
gromadzenie Tc-99m-EDDA/HYNIC-TOC w lewej półkuli 
odpowiadające przerzutowi do móżdżku raka brodawkowego 
tarczycy
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the metastases was observed by several authors [10, 11]. 
In some patients, the metastases were detected in cases 
of occult thyroid carcinoma [12, 13].
Cerebellar metastases are even less common. Only 
12 cases of metastatic changes in the cerebrum from 
DTC were reported in the literature, some of them oc-
curring as solitary distant metastasis [2, 3, 13–17]. The 
metastatic lesion in our patient was not solitary. For the 
first time, however, a previously unknown cerebellar 
metastasis was first demonstrated by SRS, while WBS 
performed after radioiodine treatment was negative.
Overexpression of somatostatin receptors, especially 
SSTR2, in neuroendocrine tumours is the basis for using 
radiolabelled analogues of this hormone for imaging 
purposes. For many years, In-111-DTPA-octreotide 
(OctreoScan) has been used in the diagnosis of neu-
roendocrine tumours. The sensitivity of this method 
reported by different authors was 51-82% in subjects 
presenting DTC with elevated Tg concentrations and 
negative WBS [18, 19]. The wide range of positive results 
can be attributed to study qualification criteria (stage of 
the disease, Tg levels) and image registration protocols.
Disadvantages of scintigraphy with In-111-DTPA-
octreotide include suboptimal energy of gamma radia-
tion emitted by In-111, higher dose equivalent obtained 
by patient and personnel, delayed time of acquisitions, 
and relatively high cost of the radiopharmaceutical. 
Therefore, introduction of new somatostatin analogues 
labelled with Tc-99m represent significant progress in 
endocrine oncology [6]. Decristoforo et al. and Gabriel 
et al. found that Tc-99m-EDDA/HYNIC-TOC scintig-
raphy provided superior scans and higher tumour/
background ratios than In-111-DTPA-octreotide [4, 5]. 
Several authors reported a high rate of positive results 
of scintigraphy with Tc-99m-EDDA/HYNIC-TOC or 
Tc-99m-EDDA/HYNIC-octreotate in different neuroen-
docrine tumours [20, 21]. The use of Tc-99m-EDDA/
HYNIC-TOC in advanced stages of DTC was also exten-
sively studied. As reported by Gabriel et al., sensitivity 
of this imaging method in patients with non-iodine avid 
DTC reached 66%, but was lower than that of 18F-FDG 
PET [7]. Also in our centre, SRS using Tc-99m-EDDA/
HYNIC-TOC has been widely used, demonstrating 
encouraging results in patients with DTC, as well as 
with medullary thyroid carcinoma [22]. Although PET 
using F-18-FDG exhibits advantageous values of sensi-
tivity and accuracy, SRS has been successfully used in 
our centre to evaluate the receptor status of endocrine 
malignancies. Similarly to neuroendocrine tumours, 
some of the patients with DTC were also experimentally 
treated with Y-90-labelled as well as with non-labelled 
(‘cold’) somatostatin analogues, with positive SRS be-
ing a major qualification criterion. Demonstration of 
positive status of metastatic changes for SRS was the 
basis for the decision on the therapy with somatostatin 
receptor analogues. Therefore, the authors decided 
that PET imaging (not widely available at the time of 
management) was not performed in our patient.
A limitation of our report is the lack of histopatho-
logical confirmation of the PTC origin of the brain le-
sion, presenting uptake of Tc-99m-EDDA/HYNIC-TOC. 
The patient died due to disseminated PTC, hence an 
autopsy was medically unwarranted. However, normal 
chromogranin A level, no signs of primary focus of 
neuroendocrine tumour, and intracerebellar localisation 
argue against neuroendocrine tumour metastasis or 
meningioma, which are the two other types of lesions 
potentially presenting the expression of somatostatin 
receptors [5, 23].
To conclude, this report demonstrates not only an 
extremely rare location of DTC metastases but also the 
utility of SRS using technetium-labelled compound in 
the diagnosis of non-iodine avid metastases.
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